Comparative Pharmacology
Head-to-head clinical analysis: FLUDROCORTISONE ACETATE versus PEDIAPRED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUDROCORTISONE ACETATE versus PEDIAPRED.
FLUDROCORTISONE ACETATE vs PEDIAPRED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mineralocorticoid receptor agonist; promotes sodium reabsorption and potassium excretion in renal distal tubules, increasing extracellular fluid volume. Also has glucocorticoid activity.
Prednisolone is a glucocorticoid receptor agonist that binds to the intracellular glucocorticoid receptor, leading to modulation of gene expression. It suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production (e.g., IL-1, IL-6, TNF-alpha). It also suppresses immune responses by reducing lymphocyte proliferation and activity.
0.1 mg orally once daily, range 0.05-0.2 mg/day
Oral: 5-60 mg/day as a single dose or divided doses; adjust based on condition and response.
None Documented
None Documented
Terminal elimination half-life is 3.5 hours (range 2–5 h); clinical effect duration exceeds half-life due to mineralocorticoid receptor binding.
2.5–3.5 hours (terminal) in children; clinical context: requires multiple daily doses for sustained effect.
Renal (80%) as inactive metabolites; less than 5% unchanged; minor biliary/fecal elimination.
Renal: ~80% as metabolites (mainly glucuronides and sulfates) and <5% unchanged; fecal: ~15%.
Category D/X
Category C
Corticosteroid
Corticosteroid